EXEL Exelixis, Inc.

NASDAQ
$51.24

Exelixis, Inc. (EXEL) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $0.79 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.2% since its last earnings release on August 5, 2026.

Exelixis Beat Expectations, Lowers Guidance
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.79 (GAAP)
Rev est $659.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $52.05

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Exelixis, Inc.

Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.

Sector

Healthcare

Industry

Biotechnology